736 related articles for article (PubMed ID: 18494810)
21. Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors.
Estacio RO
Postgrad Med; 2009 May; 121(3):33-44. PubMed ID: 19491538
[TBL] [Abstract][Full Text] [Related]
22. Anti-diabetic effect of blockade of the renin-angiotensin system.
Ando K; Fujita T
Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
[TBL] [Abstract][Full Text] [Related]
23. Clinical studies on the blockade of the renin-angiotensin-aldosterone-system.
Hennig L
Clin Nephrol; 2003 Jul; 60 Suppl 1():S53-8. PubMed ID: 12940534
[TBL] [Abstract][Full Text] [Related]
24. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
25. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
27. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
28. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
29. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
30. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
Abuissa H; Jones PG; Marso SP; O'Keefe JH
J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
[TBL] [Abstract][Full Text] [Related]
32. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
Bakris GL; Weir MR
Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
[TBL] [Abstract][Full Text] [Related]
33. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
Boucek P
Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
[TBL] [Abstract][Full Text] [Related]
34. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
35. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
Fronczyk A; Majkowska L
Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
[TBL] [Abstract][Full Text] [Related]
36. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Makkar KM; Sanoski CA; Spinler SA
Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
[TBL] [Abstract][Full Text] [Related]
37. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
38. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
Abassi Z; Winaver J; Feuerstein GZ
Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
[TBL] [Abstract][Full Text] [Related]
39. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Burnier M; Zanchi A
J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
[TBL] [Abstract][Full Text] [Related]
40. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
Perkins JM; Davis SN
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):147-52. PubMed ID: 18316950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]